Harvard Apparatus Regenerative Technology Debt to Equity Ratio 2013-2024 | HRGN
Current and historical debt to equity ratio values for Harvard Apparatus Regenerative Technology (HRGN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Harvard Apparatus Regenerative Technology debt/equity for the three months ending June 30, 2024 was 0.00.
| Harvard Apparatus Regenerative Technology Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-06-30 | $0.00B | $0.00B | -6.97 |
| 2024-03-31 | $0.00B | $0.00B | 12.80 |
| 2023-12-31 | $0.00B | $0.00B | 0.59 |
| 2023-09-30 | $0.00B | $0.00B | 0.39 |
| 2023-06-30 | $0.00B | $0.00B | 0.52 |
| 2023-03-31 | $0.01B | $-0.00B | -5.08 |
| 2022-12-31 | $0.01B | $-0.00B | -1.75 |
| 2022-09-30 | $0.01B | $-0.00B | -2.94 |
| 2022-06-30 | $0.01B | $-0.00B | -6.18 |
| 2022-03-31 | $0.01B | $-0.01B | -1.84 |
| 2021-12-31 | $0.01B | $-0.00B | -1.62 |
| 2021-09-30 | $0.00B | $0.00B | 0.25 |
| 2021-06-30 | $0.00B | $0.00B | 0.53 |
| 2021-03-31 | $0.00B | $0.00B | 2.30 |
| 2020-12-31 | $0.00B | $0.00B | 0.85 |
| 2020-09-30 | $0.00B | $0.00B | 0.50 |
| 2020-06-30 | $0.00B | $0.00B | 5.01 |
| 2020-03-31 | $0.00B | $0.00B | 1.66 |
| 2019-12-31 | $0.00B | $0.00B | 0.83 |
| 2019-09-30 | $0.00B | $0.00B | 0.84 |
| 2019-06-30 | $0.00B | $0.00B | 0.54 |
| 2019-03-31 | $0.00B | $0.00B | 0.75 |
| 2018-12-31 | $0.00B | $0.00B | 0.34 |
| 2018-09-30 | $0.00B | $0.00B | 0.27 |
| 2018-06-30 | $0.00B | $0.01B | 0.25 |
| 2018-03-31 | $0.00B | $0.00B | 0.27 |
| 2017-12-31 | $0.00B | $0.00B | 0.47 |
| 2017-09-30 | $0.00B | $0.00B | 4.35 |
| 2017-06-30 | $0.00B | $0.00B | 2.64 |
| 2017-03-31 | $0.01B | $0.00B | 4.22 |
| 2016-12-31 | $0.00B | $0.00B | 1.57 |
| 2016-09-30 | $0.00B | $0.01B | 0.50 |
| 2016-06-30 | $0.00B | $0.01B | 0.26 |
| 2016-03-31 | $0.00B | $0.01B | 0.06 |
| 2015-12-31 | $0.00B | $0.01B | 0.08 |
| 2015-09-30 | $0.00B | $0.01B | 0.04 |
| 2015-06-30 | $0.00B | $0.01B | 0.05 |
| 2015-03-31 | $0.00B | $0.01B | 0.05 |
| 2014-12-31 | $0.00B | $0.01B | 0.11 |
| 2014-09-30 | $0.00B | $0.01B | 0.08 |
| 2014-06-30 | $0.00B | $0.01B | 0.08 |
| 2014-03-31 | $0.00B | $0.01B | 0.07 |
| 2013-12-31 | $0.00B | $0.02B | 0.03 |
| 2013-09-30 | $0.00B | $0.00B | 3.33 |
| 2013-06-30 | $0.00B | $0.00B | 0.00 |
| 2013-03-31 | $0.00B | $0.00B | 0.00 |
| 2012-12-31 | $0.00B | 0.00 | |
| 2012-09-30 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.059B | $0.000B |
| Harvard Apparatus Regenerative Technology Inc. provide greater clarity and visibility for its regenerative technology and expanding strategy on rejuvenation. Harvard Apparatus Regenerative Technology Inc., formerly known as Biostage Inc., is based in HOLLISTON, Mass. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $96.890B | 12.02 |
| Cencora (COR) | United States | $46.107B | 17.62 |
| DiDi Global (DIDIY) | China | $23.233B | 0.00 |
| ICON (ICLR) | Ireland | $18.679B | 16.64 |
| Revvity (RVTY) | United States | $15.535B | 26.63 |
| Avantor (AVTR) | United States | $15.498B | 23.24 |
| Natera (NTRA) | United States | $15.385B | 0.00 |
| Viatris (VTRS) | United States | $13.858B | 4.22 |
| BioMerieux (BMXMF) | France | $13.601B | 0.00 |
| Solventum (SOLV) | United States | $12.636B | 0.00 |
| CochLear (CHEOY) | Australia | $12.565B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.202B | 28.74 |
| Charles River Laboratories (CRL) | United States | $9.742B | 18.41 |
| Sonic Healthcare (SKHHY) | Australia | $8.273B | 0.00 |
| HealthEquity (HQY) | United States | $7.792B | 42.29 |
| Doximity (DOCS) | United States | $7.787B | 49.34 |
| Bausch + Lomb (BLCO) | Canada | $6.975B | 32.47 |
| Life Times (LTH) | United States | $4.762B | 31.52 |
| PACS (PACS) | United States | $4.502B | 0.00 |
| Sotera Health (SHC) | United States | $4.367B | 23.36 |
| Organon (OGN) | United States | $4.239B | 4.28 |
| Surgery Partners (SGRY) | United States | $3.778B | 41.86 |
| BrightSpring Health Services (BTSG) | United States | $3.070B | 65.30 |
| Ardent Health Partners (ARDT) | United States | $2.577B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.546B | 0.00 |
| Concentras Parent (CON) | United States | $2.480B | 0.00 |
| Premier (PINC) | United States | $2.271B | 11.34 |
| GoodRx Holdings (GDRX) | United States | $2.254B | 84.86 |
| GeneDx Holdings (WGS) | United States | $2.057B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.575B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.507B | 7.57 |
| Progyny (PGNY) | United States | $1.425B | 25.06 |
| Establishment Labs Holdings (ESTA) | $1.338B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.319B | 12.91 |
| CareDx (CDNA) | United States | $1.228B | 0.00 |
| Agilon Health (AGL) | United States | $1.123B | 0.00 |
| Embecta (EMBC) | United States | $0.864B | 5.76 |
| InnovAge Holding (INNV) | United States | $0.822B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| SBC Medicals (SBC) | United States | $0.722B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.488B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.483B | 0.00 |
| Enhabit (EHAB) | United States | $0.382B | 33.04 |
| DocGo (DCGO) | United States | $0.355B | 13.35 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.309B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.255B | 0.00 |
| ModivCare (MODV) | United States | $0.232B | 7.37 |
| Beauty Health (SKIN) | United States | $0.211B | 0.00 |
| Biodesix (BDSX) | United States | $0.195B | 0.00 |
| LifeMD (LFMD) | United States | $0.192B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.178B | 0.00 |
| MultiPlan (MPLN) | United States | $0.136B | 0.00 |
| Nutex Health (NUTX) | United States | $0.127B | 0.00 |
| So-Young (SY) | China | $0.092B | 22.35 |
| Singular Genomics Systems (OMIC) | United States | $0.057B | 0.00 |
| OncoCyte (OCX) | United States | $0.049B | 0.00 |
| NeueHealth (NEUE) | United States | $0.041B | 1.63 |
| Co-Diagnostics (CODX) | United States | $0.039B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.036B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.027B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| Oncology Institute (TOI) | United States | $0.021B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| KindlyMD (KDLY) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |